Cytomegalovirus Infection of the Anterior Segment: Corneal Endotheliitis and Secondary Glaucoma

Read full text
Authors: Fan Liu, Yaru Zou, Mingming Yang, Jing Zhang, Kyoko Ohno-Matsui, Koju Kamoi
Cited by: 1
References: 153

Abstract

Cytomegalovirus (CMV) infection of the anterior segment is increasingly recognized as an important cause of corneal endotheliitis and secondary glaucoma, even in immunocompetent individuals. CMV corneal endotheliitis typically presents with coin-shaped or linear keratic precipitates (KPs), corneal edema, mild anterior chamber inflammation, and recurrent intraocular pressure (IOP) elevation; persistent or episodic ocular hypertension may progress to glaucomatous optic neuropathy if inadequately treated. Definitive diagnosis relies on aqueous humor polymerase chain reaction (PCR) testing for CMV DNA, supported by adjunctive imaging including specular microscopy, anterior segment optical coherence tomography (AS-OCT), and in vivo confocal microscopy (IVCM). Management requires a comprehensive strategy integrating antiviral therapy, anti-inflammatory treatment, and appropriate IOP control. Topical or systemic ganciclovir remains the cornerstone, while refractory disease may necessitate surgical intervention. Older age and male sex, host immune status, prolonged or recurrent CMV infection, and pre-existing ocular conditions are major risk factors for progression and poor outcomes. The pathogenesis of secondary glaucoma is thought to involve both direct viral cytopathic effects and inflammation-mediated damage to the trabecular meshwork (TM), resulting in impaired aqueous outflow. Therefore, early recognition, accurate diagnosis, and effective treatment are essential to prevent corneal decompensation and permanent vision loss.

Fields of Study & Subjects

Ocular Diseases and Behçet’s Syndrome Cytomegalovirus and herpesvirus research Ocular Infections and Treatments

Publication details

Journal / source
Pathogens
Publisher
MDPI AG
Volume
15
Issue
4
Pages
371–371
Publication date
31 March 2026
Language
EN